Margaret B Pulsifer1, Roshan V Sethi2, Karen A Kuhlthau3, Shannon M MacDonald2, Nancy J Tarbell2, Torunn I Yock2. 1. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: mpulsifer@mgh.harvard.edu. 2. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
PURPOSE: To report, from a longitudinal study, cognitive outcome in pediatric patients treated with proton radiation therapy (PRT) for central nervous system (CNS) tumors. METHODS AND MATERIALS: Sixty patients receiving PRT for medulloblastoma (38.3%), gliomas (18.3%), craniopharyngioma (15.0%), ependymoma (11.7%), and other CNS tumors (16.7%) were administered age-appropriate measures of cognitive abilities at or near PRT initiation (baseline) and afterward (follow-up). Patients were aged ≥ 6 years at baseline to ensure consistency in neurocognitive measures. RESULTS: Mean age was 12.3 years at baseline; mean follow-up interval was 2.5 years. Treatment included prior surgical resection (76.7%) and chemotherapy (61.7%). Proton radiation therapy included craniospinal irradiation (46.7%) and partial brain radiation (53.3%). At baseline, mean Wechsler Full Scale IQ was 104.6; means of all 4 Index scores were also in the average range. At follow-up, no significant change was observed in mean Wechsler Full Scale IQ, Verbal Comprehension, Perceptual Reasoning/Organization, or Working Memory. However, Processing Speed scores declined significantly (mean 5.2 points), with a significantly greater decline for subjects aged <12 years at baseline and those with the highest baseline scores. Cognitive outcome was not significantly related to gender, extent of radiation, radiation dose, tumor location, histology, socioeconomic status, chemotherapy, or history of surgical resection. CONCLUSIONS: Early cognitive outcomes after PRT for pediatric CNS tumors are encouraging, compared with published outcomes from photon radiation therapy.
PURPOSE: To report, from a longitudinal study, cognitive outcome in pediatric patients treated with proton radiation therapy (PRT) for central nervous system (CNS) tumors. METHODS AND MATERIALS: Sixty patients receiving PRT for medulloblastoma (38.3%), gliomas (18.3%), craniopharyngioma (15.0%), ependymoma (11.7%), and other CNS tumors (16.7%) were administered age-appropriate measures of cognitive abilities at or near PRT initiation (baseline) and afterward (follow-up). Patients were aged ≥ 6 years at baseline to ensure consistency in neurocognitive measures. RESULTS: Mean age was 12.3 years at baseline; mean follow-up interval was 2.5 years. Treatment included prior surgical resection (76.7%) and chemotherapy (61.7%). Proton radiation therapy included craniospinal irradiation (46.7%) and partial brain radiation (53.3%). At baseline, mean Wechsler Full Scale IQ was 104.6; means of all 4 Index scores were also in the average range. At follow-up, no significant change was observed in mean Wechsler Full Scale IQ, Verbal Comprehension, Perceptual Reasoning/Organization, or Working Memory. However, Processing Speed scores declined significantly (mean 5.2 points), with a significantly greater decline for subjects aged <12 years at baseline and those with the highest baseline scores. Cognitive outcome was not significantly related to gender, extent of radiation, radiation dose, tumor location, histology, socioeconomic status, chemotherapy, or history of surgical resection. CONCLUSIONS: Early cognitive outcomes after PRT for pediatric CNS tumors are encouraging, compared with published outcomes from photon radiation therapy.
Authors: Marieke A de Ruiter; Rosa van Mourik; Antoinette Y N Schouten-van Meeteren; Martha A Grootenhuis; Jaap Oosterlaan Journal: Dev Med Child Neurol Date: 2012-11-15 Impact factor: 5.449
Authors: S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: R K Mulhern; S L Palmer; W E Reddick; J O Glass; L E Kun; J Taylor; J Langston; A Gajjar Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544
Authors: Julie A Grieco; Annah N Abrams; Casey L Evans; Torunn I Yock; Margaret B Pulsifer Journal: Childs Nerv Syst Date: 2019-07-19 Impact factor: 1.475
Authors: Tanya N Antonini; M Douglas Ris; David R Grosshans; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold Paulino; Amanda E Child; Jessica Orobio; Heather H Stancel; Lisa S Kahalley Journal: Radiother Oncol Date: 2017-06-24 Impact factor: 6.280
Authors: Lisa S Kahalley; M Douglas Ris; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold C Paulino; William E Whitehead; Charles G Minard; Heather H Stancel; Jessica Orobio; Judy J Xue; Emily A Warren; David R Grosshans Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300
Authors: Lea M Ventura; Julie A Grieco; Casey L Evans; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock; Margaret B Pulsifer Journal: J Neurooncol Date: 2017-12-06 Impact factor: 4.130
Authors: Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock Journal: Neuro Oncol Date: 2020-09-29 Impact factor: 12.300